Answers are grounded in this paper and cite their sources.
Background There is considerable interindividual variability in the risk of developing or worsening gastroesophageal reflux disease (GERD) after Helicobacter pylori (H. pylori) eradication therapy, and the contributing factors remain incompletely elucidated. An abnormal gastroesophageal flap valve (GEFV) is a known anatomical factor associated with GERD, but its association with post-eradication symptom burden remains unclear. This retrospective comparative cohort study aimed to investigate whether GEFV abnormality was independently associated with higher 6-month GerdQ scores after H. pylori eradication, after adjusting for baseline symptom severity and other clinically relevant prespecified covariates. Methods We retrospectively enrolled patients who underwent upper gastrointestinal endoscopy and H. pylori eradication therapy at Jinjiang Municipal Hospital between October 2023 and December 2025. The exposed group included 122 H. pylori-infected patients with abnormal GEFV. The unexposed group included 135 H. pylori-infected patients with normal GEFV. We collected baseline and 6-month post-treatment GerdQ scores, as well as age, sex, BMI, alcohol use, smoking, endoscopic reflux esophagitis grade, and gastric mucosal atrophy grade. A retrospective comparative cohort study was conducted. Multiple linear regression was performed to identify factors associated with the 6-month GerdQ score, adjusting for baseline GerdQ score and clinically relevant prespecified covariates. Results Statistically significant differences were observed between the abnormal-GEFV and normal-GEFV groups in sex distribution, smoking history, detection rate of reflux esophagitis, and both baseline and post-treatment GerdQ scores (all P < 0.05). In the multiple linear regression model, after adjusting for baseline GerdQ score and other prespecified covariates, GEFV abnormality (B = 0.788, 95% CI: 0.447–1.130, P < 0.001) and moderate-to-severe gastric atrophy (B = 1.573, 95% CI: 0.881–2.265, P < 0.001) were independently associated with higher 6-month GerdQ scores. Baseline GerdQ score was the strongest determinant of the 6-month score (B = 0.666, 95% CI: 0.599–0.732, P < 0.001). Sex, age, BMI, smoking, and reflux esophagitis were not significantly associated with the outcome. Conclusions Endoscopic GEFV grading may serve as a potential anatomical indicator of higher post-eradication symptom burden, independent of baseline symptom severity, while moderate-to-severe atrophy showed a similar but less stable association. Given the exploratory nature of the model, the lack of internal and external validation, and the potential sparse-data bias, these findings require confirmation in future prospective multicenter studies before any clinical application.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: